LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Home・Akciju saraksts・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Slēgts

28.73 -0.28

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

28.33

Max

28.77

Galvenie mērījumi
By Trading Economics
Ienākumi	43M 13M
Pārdošana	29M 107M
EPS	0.25
Peļņas marža	12.139
Darbinieki	524
EBITDA	16M 8.2M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+124.82% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 6. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	17M 1.5B
Iepriekšējā atvēršanas cena	29.01
Iepriekšējā slēgšanas cena	28.73

Immunocore Holdings PLC ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 29. maijs 23:08 UTC

Iegādes, apvienošanās, pārņemšana

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

2026. g. 29. maijs 23:06 UTC

Iegādes, apvienošanās, pārņemšana

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

2026. g. 29. maijs 20:53 UTC

Peļņas

Oil Declines Lift Stocks to Fresh Records -- WSJ

2026. g. 29. maijs 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 29. maijs 20:33 UTC

Tirgus saruna

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

2026. g. 29. maijs 20:11 UTC

Peļņas

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

2026. g. 29. maijs 19:47 UTC

Peļņas

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

2026. g. 29. maijs 19:36 UTC

Tirgus saruna

U.S. Natural Gas Futures End Month With Gains -- Market Talk

2026. g. 29. maijs 19:34 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 29. maijs 19:34 UTC

Tirgus saruna

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

2026. g. 29. maijs 19:22 UTC

Tirgus saruna

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

2026. g. 29. maijs 19:05 UTC

Iegādes, apvienošanās, pārņemšana

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

2026. g. 29. maijs 18:19 UTC

Tirgus saruna

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

2026. g. 29. maijs 18:12 UTC

Iegādes, apvienošanās, pārņemšana

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

2026. g. 29. maijs 18:11 UTC

Tirgus saruna

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

2026. g. 29. maijs 18:10 UTC

Tirgus saruna

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

2026. g. 29. maijs 17:55 UTC

Peļņas

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

2026. g. 29. maijs 17:55 UTC

Tirgus saruna

NEAR Protocol Nearly Doubles in May -- Market Talk

2026. g. 29. maijs 17:38 UTC

Tirgus saruna

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

2026. g. 29. maijs 17:00 UTC

Peļņas

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

2026. g. 29. maijs 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 29. maijs 16:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 29. maijs 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 29. maijs 16:02 UTC

Tirgus saruna

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

2026. g. 29. maijs 15:55 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 29. maijs 15:55 UTC

Tirgus saruna

Cryptocurrencies Appear Detached From Stocks -- Market Talk

2026. g. 29. maijs 15:50 UTC

Iegādes, apvienošanās, pārņemšana

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

2026. g. 29. maijs 15:50 UTC

Iegādes, apvienošanās, pārņemšana

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

2026. g. 29. maijs 15:40 UTC

Tirgus saruna

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

2026. g. 29. maijs 15:20 UTC

Tirgus saruna

Canada's Economy Not Looking All That Bright -- Market Talk

Salīdzinājums

Cenas izmaiņa

Immunocore Holdings PLC ADR Prognoze

Cenas mērķis

By TipRanks

124.82% augšup

Prognoze 12 mēnešiem

Vidējais 65.13 USD 124.82%

Augstākais 100 USD

Zemākais 33 USD

Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Immunocore Holdings PLC ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

9 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 9 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Immunocore Holdings PLC ADR — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.